Minutes General Meeting Minutes General Meeting Regulatory release 15 May 2024, 8.00 am CET Kinepolis Group NV has held her Ordinary General Meeting on 8 May 2024. All proposed agenda items were approved.The minutes of the meeting can be consulted on the website of Kinepolis Group KINEPOLIS GROUP NV Eeuwfeestlaan 20, 1020 BrusselsEnterprise Number VAT BE 0415.928.179 RLP Brussels, Dutch speaking department -
Procès-Verbal de l’Assemblée générale Procès-Verbal de l’Assemblée générale Information réglementée 15 mai 2024, 8h00 L’Assemblée générale ordinaire de Kinepolis Group SA s’est tenue en date du 8 mai 2024. Tous les points de l’ordre du jour ont été approuvés. Le procès-verbal de l’assemblée peut être consulté sur le site web de Kinepolis Group KINEPOLIS GROUP SA Boulevard du Centenaire 20, 1020 BruxellesN° d'entreprise TVA BE 0415.928.179 RPM Bruxelles, département néerlandophone -
Notulen Algemene Vergadering Notulen Algemene Vergadering Gereglementeerde informatie 15 mei 2024, 8u00 Kinepolis Group NV heeft op 8 mei 2024 een Gewone Algemene Vergadering gehouden. Alle voorgestelde agendapunten werden goedgekeurd.De notulen van de vergadering zijn te raadplegen op de website van Kinepolis Group NV KINEPOLIS GROUP NV Eeuwfeestlaan 20, 1020 BrusselOndernemingsnummer BTW BE 0415.928.179 RPR Brussel, Nederlandstalige afdeling -
>Q1 in line on sales, below on EBIT - Q1 sales grew by 83% y-o-y and 6% q-o-q to $ 398m (US $ 347m, Japan $ 18m and EMEA $ 31m), reflecting the strong medical need in myasthenia gravis, the quality of products (i.e. Vyvgart and Vyvgart Hytrulo), as well as the excellent execution of the commercial rollout. The product should remain on this growth trajectory to achieve peak sales estimated at $ 11bn (vs the consensus at $ 11bn) in 2035, driven by the recent launch of ...
This morning argenx reported its 1Q24 update, highlighting $ 398m sales and its pipeline progress. Mgmt is fully focused on expanding its commercial footprint into CIDP (PDUFA: June 21). Meanwhile, AAV was scrapped from the pipeline and systemic sclerosis (SSC) added. We maintain our € 435 TP and Buy rating.
>T1 en ligne sur les ventes, en dessous sur l’EBIT - Les ventes T1 progressent de 83% y-o-y et de 6% q-o-q pour atteindre 398 M$ (US 347 M$, Japon 18 M$ et EMEA 31 M$), reflétant le fort besoin médical dans la Myasthénie Gravis, la qualité des produits (i.e. Vyvgart et Vyvgart Hytrulo), ainsi que l’excellente exécution du déploiement commercial. Le produit devrait rester sur cette trajectoire de croissance pour atteindre un peak sales estimé à 11 Md$ (vs css 11 Md$) ...
argenx Reports First Quarter 2024 Financial Results and Provides Business Update $398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in second quarter 2024 Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 9, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its fi...
• Argenx published its Q1 update in which VYVGARD revenues slightly beat CSS by 2%• Two key news items: 1/ filing for the pre-filled syringe syringe for gMG and CIDP to be submitted in Q2 24 and 2/ decision to discontinue the planned development of efgartigimod in ANCA-associated vasculitis (AAV) following risk assessment of all ongoing studies based on learnings from ADDRESS and ADVANCE SC studies. CIDP PDUFA target action date of June 21 reiterated• Cash position stood at USD 3.1bn end of Marc...
Payment of dividend Payment of dividend Regulatory release 8 May 2024, 2 p.m. The Ordinary General Meeting of Kinepolis Group NV has decided today to pay out a dividend of € 0,55 gross per share to the shareholders (€ 0,385 net after deduction of 30% withholding taxes). The dividend will be paid out as from 15 May 2024. The ex coupon date is fixed at 13 May 2024 and the record date at 14 May 2024. KINEPOLIS GROUP NV Public limited company that is making or has made a public appeal to savingsEeuwfeestlaan 20, 1020 BrusselsEnterprise Number VAT BE 0415.928.179 RLP Brussels
argenx announces results of Annual General Meeting of Shareholders May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held today. All items on the agenda received a majority of votes in favor except for agenda item 5 (adoption of the remuneration policy). As part of the approved resolutions: The Company's annual report and annual accounts for the financial year ending...
argenx to Present at BofA Securities 2024 Health Care Conference May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in a fireside chat at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 10:00 AM PT in Las Vegas, NV. A live webcast of the fireside chat may be accessed on the Investors section of the argenx website at . A replay of the webcast will be availabl...
Kinepolis: Weak US/Canada box office and France attendance in April. NSI: FS NL Holdings acquires c.10% from ICAMAP for c.€43m. PostNL: 1Q24 touch below; FY24 outlook reiterated and parcel volumes accelerate. Staffing: US temp volume trend still soft but stable, NFP jobs miss. TKH Group: A weak quarter indeed
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024 May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 9, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2024 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at . A replay of the ...
Nextensa NV/SA : Information on the total number of voting rights and shares PRESS RELEASE REGULATED INFORMATIONBrussels, 30 April 2024 17h40 Nextensa NV/SA : Information on the total number of voting rights and shares In application of article 15 of the Law of 2 May 2007 on disclosure of major shareholdings, Nextensa (the 'Company') announces the following information following the loss of double voting rights attached to registered shares. Situation on 30 April 2024: Total capital: EUR 109,997,148.34Total number of secu...
Nextensa SA: Informations relatives au nombre total de droits de vote et d'actions COMMUNIQUÉ DE PRESSE INFORMATIONS RÉGLEMENTÉEBruxelles, 30 avril 2024 17h40 Nextensa SA: Informations relatives au nombre total de droits de vote et d'actions En application de l'article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nextensa (la ‘Société’) communique les informations suivantes suite à la perte des droits de vote double attachés aux actions nominatives. Situation au 30 avril 2024 : Total du capital: ...
Azelis: Strong margin performance in weak trading results in 3% EBITA beat. BE Semiconductor Industries: 1Q24 results; prolonged downcycle. Coca-Cola Europacific Partners plc: Messy but good. DWS: Record breaking. Flow Traders: Crypto Kings. Fugro: Here we go again. Kinepolis: Weak start to the year, but a bit better than feared. UCB: Changes in the group executive committee. Unilever: Heading in the right direction. Vonovia: Disposal of 4,500 apartments for €700m. Wolters Kl...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.